Reduced Intensity Conditioning for MDS

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions
MDS
Interventions
DRUG

Fludarabine; melphalan; busulfan

The conditioning regimen includes fludarabine, busulfan, and melphalan, with a transplant conditioning intensity of 3.0. The RIC is used in the allo-HCT in the MDS patients.

Trial Locations (1)

Unknown

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Wuhan TongJi Hospital

OTHER

collaborator

Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology

UNKNOWN

collaborator

Zhejiang University

OTHER

lead

Ruijin Hospital

OTHER